Solid Biosciences Inc. (NASDAQ: SLDB) disclosed a sale by its chief financial officer, Kevin Tan, who sold 26,837 shares of the company's common stock on February 2, 2026. The transactions, recorded on a Form 4 filed with the Securities and Exchange Commission, produced proceeds of roughly $172,747 based on an average price of $6.4369 per share.
The block was executed in multiple trades at prices spanning $6.295 to $6.580 per share. The sale price was close to the stock's trading level cited in the filing, $6.42, in a name that has climbed just over 104% in the past year, according to InvestingPro data included in the disclosure.
Company filings indicate the sale was carried out to meet withholding tax obligations that arose after previously granted Performance Stock Units vested. In related activity, Tan converted awards into equity earlier in the week, acquiring a total of 89,721 shares of Solid Biosciences common stock through conversions of performance stock units and restricted stock units on January 29 and January 31.
InvestingPro commentary included with the disclosure noted balance sheet dynamics: Solid Biosciences holds more cash than debt, yet the company is depleting cash rapidly and is not anticipated to be profitable in the current year. Market participants and analysts continue to model upside - price targets cited in the report range from $11 to $20, implying potential appreciation from the trading level noted in the filing.
Solid Biosciences' market capitalization is reported at about $499 million. InvestingPro's assessment referenced in the disclosure places the stock slightly below its Fair Value estimate. The filing and accompanying research notes point readers to additional InvestingPro tools and reports for a deeper look at valuation, momentum, and other metrics.
Clinical and regulatory updates included in the company overview
The disclosure also summarized recent operational progress. Solid Biosciences has dosed 33 participants in its Phase 1/2 INSPIRE DUCHENNE clinical trial for Duchenne muscular dystrophy; the company reported that its SGT-003 gene therapy has been generally well tolerated among those participants. Separately, the U.S. Food and Drug Administration granted Orphan Drug designation to SGT-212, Solid Biosciences' investigational gene therapy candidate for Friedreich's ataxia.
Additionally, the company reported dosing the first participant in the Phase 1b FALCON clinical trial for SGT-212, which employs a dual-route administration strategy intended to address neurologic, cardiac, and systemic aspects of the disease.
Investor sentiment captured in the filing highlights that Citizens reiterated a Market Outperform rating on the stock, pointing to the company’s proprietary capsid technology and a unique dystrophin construct as strengths. The disclosure also notes that the U.S. Department of Health and Human Services has added Duchenne muscular dystrophy to the Recommended Uniform Screening Panel, a development Solid Biosciences supports to facilitate earlier detection and access to treatment.
Context and limitations
The Form 4 filing specifies the motives for the sale - covering tax withholding - and details recent equity conversions by the CFO, but it does not alter or provide new guidance on company financial forecasts beyond the InvestingPro analysis referenced. The disclosure compiles both the insider transaction details and a summary of recent corporate and clinical milestones without expanding on future financing plans or timelines.